AU2002333271B2 - Crystalline forms of fluvastatin sodium - Google Patents

Crystalline forms of fluvastatin sodium Download PDF

Info

Publication number
AU2002333271B2
AU2002333271B2 AU2002333271A AU2002333271A AU2002333271B2 AU 2002333271 B2 AU2002333271 B2 AU 2002333271B2 AU 2002333271 A AU2002333271 A AU 2002333271A AU 2002333271 A AU2002333271 A AU 2002333271A AU 2002333271 B2 AU2002333271 B2 AU 2002333271B2
Authority
AU
Australia
Prior art keywords
intensity
preparation
fluvastatin sodium
crystalline polymorph
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002333271A
Other languages
English (en)
Other versions
AU2002333271A1 (en
Inventor
Andreas Burkhard
Claudia Marcolli
Martin Szelagiewicz
Paul Adriaan Van Der Schaaf
Annemarie Wolleb
Heinz Wolleb
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF Schweiz AG
Original Assignee
Ciba Spezialitaetenchemie Holding AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Spezialitaetenchemie Holding AG filed Critical Ciba Spezialitaetenchemie Holding AG
Publication of AU2002333271A1 publication Critical patent/AU2002333271A1/en
Application granted granted Critical
Publication of AU2002333271B2 publication Critical patent/AU2002333271B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
    • C07F1/04—Sodium compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
AU2002333271A 2001-08-03 2002-07-25 Crystalline forms of fluvastatin sodium Ceased AU2002333271B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01810756.5 2001-08-03
EP01810756 2001-08-03
PCT/EP2002/008276 WO2003013512A2 (en) 2001-08-03 2002-07-25 Crystalline forms of fluvastatin sodium

Publications (2)

Publication Number Publication Date
AU2002333271A1 AU2002333271A1 (en) 2003-06-19
AU2002333271B2 true AU2002333271B2 (en) 2007-08-09

Family

ID=8184071

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002333271A Ceased AU2002333271B2 (en) 2001-08-03 2002-07-25 Crystalline forms of fluvastatin sodium

Country Status (16)

Country Link
US (1) US6696479B2 (enExample)
EP (1) EP1429757B8 (enExample)
JP (2) JP4681808B2 (enExample)
KR (1) KR100975782B1 (enExample)
CN (2) CN1536999B (enExample)
AR (1) AR036205A1 (enExample)
AT (1) ATE391502T1 (enExample)
AU (1) AU2002333271B2 (enExample)
CA (1) CA2454072A1 (enExample)
DE (1) DE60226044T2 (enExample)
ES (1) ES2304140T3 (enExample)
HU (1) HUP0401141A3 (enExample)
IL (2) IL159861A0 (enExample)
PL (1) PL366905A1 (enExample)
RU (1) RU2334738C2 (enExample)
WO (1) WO2003013512A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7087631B2 (en) * 2002-07-18 2006-08-08 Inotek Pharmaceuticals Corporation Aryltetrazole compounds, and compositions thereof
AU2003250086A1 (en) * 2002-07-26 2004-02-23 Ciba Specialty Chemicals Holging Inc. Crystalline polymorphic and amorphous forms of benazepril hydrochloride
WO2004096765A2 (en) * 2003-05-01 2004-11-11 Morepen Laboratories Ltd. A novel crystalline polymorph of fluvastatin sodium and a process for preparing it
US7368581B2 (en) 2003-06-18 2008-05-06 Teva Pharmaceutical Industries Ltd. Process for the preparation of fluvastatin sodium crystal from XIV
EP1790634A3 (en) * 2003-06-18 2007-06-13 Teva Pharmaceutical Industries Ltd. Fluvastatin sodium crystal form and processes for preparing it
US7368468B2 (en) * 2003-06-18 2008-05-06 Teva Pharmaceutical Industries Ltd. Fluvastatin sodium crystal forms XIV, LXXIII, LXXIX, LXXX and LXXXVII, processes for preparing them, compositions containing them and methods of using them
JP2007510136A (ja) * 2003-10-06 2007-04-19 ソルヴィーアス　アクチェンゲゼルシャフト 分子状固体の結晶形態を並行検出する方法
WO2005037787A1 (en) * 2003-10-16 2005-04-28 Ciba Specialty Chemicals Holding Inc. Crystalline form of fluvastatin sodium
US20070179166A1 (en) * 2003-12-24 2007-08-02 Valerie Niddam-Hildesheim Process for preparation of statins with high syn to anti ratio
US7851624B2 (en) * 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
WO2005080332A1 (en) * 2004-01-14 2005-09-01 Cadila Healthcare Limited Novel form of fluvastatin sodium
EP1711493A2 (en) * 2004-02-06 2006-10-18 CIBA SPECIALTY CHEMICALS HOLDING INC. Patent Departement Crystalline forms of zolmitriptan
US7241800B2 (en) 2004-03-17 2007-07-10 Mai De Ltd. Anhydrous amorphous form of fluvastatin sodium
WO2006021967A1 (en) * 2004-08-26 2006-03-02 Biocon Limited Process for the preparation of fluvastatin sodium form a.
WO2006030304A2 (en) * 2004-09-17 2006-03-23 Ranbaxy Laboratories Limited Novel forms of fluvastatin sodium, processes for preparation and pharmaceutical compositions thereof
WO2006085338A2 (en) * 2005-02-11 2006-08-17 Jubilant Organosys Limited Novel polymorphic forms of fluvastatin sodium and process for preparing the same
WO2006109147A1 (en) * 2005-04-12 2006-10-19 Glenmark Pharmaceuticals Limited Substantially pure amorphous fluvastatin, processes for its preparation and pharmaceutical compositions containing same
WO2007039784A2 (en) * 2005-10-06 2007-04-12 Wockhardt Limited A novel crystalline polymorph of fluvastatin sodium and process for preparing it
EP1948637A4 (en) * 2005-11-14 2010-09-08 Hetero Drugs Ltd PROCESS FOR AMORPHES ESOMEPRAZOLE
KR20080005230A (ko) * 2006-02-27 2008-01-10 테바 파마슈티컬 인더스트리즈 리미티드 플루바스타틴 나트륨 신규 형태 및 이의 제조 방법
WO2009122425A1 (en) * 2008-04-04 2009-10-08 Shodhana Laboratories Limited Novel crystalline form of carvedilol dihydrogen phosphate and related processes
CN101684121B (zh) * 2008-09-22 2013-04-03 重庆医药工业研究院有限责任公司 培美曲塞二酸的新晶型及其制备方法
JP6115288B2 (ja) * 2012-04-27 2017-04-19 株式会社島津製作所 質量分析におけるピーク検出方法及びそのシステム
TW201806928A (zh) * 2016-07-01 2018-03-01 第一三共股份有限公司 胺基羧酸之酸加成鹽的結晶及其製造方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4739073A (en) * 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
HU204253B (en) * 1982-11-22 1991-12-30 Sandoz Ag Process for producing mevalonolactone analogues and derivatives and pharmaceutical compositions containing them
JPS60500015A (ja) * 1982-11-22 1985-01-10 サンド・アクチエンゲゼルシヤフト メバロラクトン同族体とその誘導体、これらの製造法およびこれらを含有する製薬学的組成物
HU9203780D0 (en) * 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
HRP960313B1 (en) * 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
DE69719755T2 (de) * 1996-06-24 2003-11-20 Novartis Ag, Basel Polymorphe verbindungen
JP2004513112A (ja) * 2000-10-31 2004-04-30 チバ　スペシャルティ　ケミカルズ　ホールディング　インコーポレーテッド フルバスタチンナトリウムの結晶形

Also Published As

Publication number Publication date
HUP0401141A3 (en) 2011-07-28
JP4681808B2 (ja) 2011-05-11
HUP0401141A2 (hu) 2004-09-28
WO2003013512A3 (en) 2003-11-20
CN102516150A (zh) 2012-06-27
IL159861A0 (en) 2004-06-20
CN1536999A (zh) 2004-10-13
KR20040022226A (ko) 2004-03-11
EP1429757A2 (en) 2004-06-23
EP1429757B8 (en) 2008-07-16
US20030032666A1 (en) 2003-02-13
CN1536999B (zh) 2012-08-08
US6696479B2 (en) 2004-02-24
AR036205A1 (es) 2004-08-18
CA2454072A1 (en) 2003-02-20
JP2010265308A (ja) 2010-11-25
ES2304140T3 (es) 2008-09-16
KR100975782B1 (ko) 2010-08-17
ATE391502T1 (de) 2008-04-15
IL159861A (en) 2009-02-11
PL366905A1 (en) 2005-02-07
RU2004106528A (ru) 2005-07-27
JP2005501838A (ja) 2005-01-20
WO2003013512A2 (en) 2003-02-20
EP1429757B1 (en) 2008-04-09
DE60226044T2 (de) 2009-05-14
RU2334738C2 (ru) 2008-09-27
DE60226044D1 (de) 2008-05-21

Similar Documents

Publication Publication Date Title
US6696479B2 (en) Crystalline forms
AU2002333271A1 (en) Crystalline forms of fluvastatin sodium
US6858643B2 (en) Crystalline forms of Fluvastatin sodium
US7538136B2 (en) Crystalline forms of atorvastatin
JP4282092B2 (ja) 多形性化合物
AU2002223639A1 (en) Crystalline forms of fluvastatin sodium
US6906087B2 (en) Crystalline forms of venlafaxine hydrochloride
US20040063961A1 (en) Crystalline forms of cerivastatin sodium
EP1102745B1 (en) A process for the preparation of zofenopril calcium salt
US7432380B2 (en) Crystalline form of Fluvastatin sodium
WO2006030304A2 (en) Novel forms of fluvastatin sodium, processes for preparation and pharmaceutical compositions thereof
WO2007039784A2 (en) A novel crystalline polymorph of fluvastatin sodium and process for preparing it

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired